This company has been marked as potentially delisted and may not be actively trading. Innovate Biopharmaceuticals (INNT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock INNT vs. SCPS, VAXX, EVLO, CMRA, ARDS, STAB, CLVR, EFTR, MTEM, and ONCSQShould you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), Molecular Templates (MTEM), and OncoSec Medical (ONCSQ). These companies are all part of the "medical" sector. Innovate Biopharmaceuticals vs. Its Competitors Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Statera Biopharma Clever Leaves eFFECTOR Therapeutics Molecular Templates OncoSec Medical Innovate Biopharmaceuticals (NASDAQ:INNT) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations. Do institutionals & insiders hold more shares of INNT or SCPS? 5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. 7.9% of Innovate Biopharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor INNT or SCPS? In the previous week, Innovate Biopharmaceuticals' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Innovate Biopharmaceuticals Neutral Scopus BioPharma Neutral Is INNT or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Innovate BiopharmaceuticalsN/A N/A -234.42% Scopus BioPharma N/A N/A N/A Which has more volatility & risk, INNT or SCPS? Innovate Biopharmaceuticals has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Which has higher valuation and earnings, INNT or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnovate BiopharmaceuticalsN/AN/A-$27.05MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A SummaryScopus BioPharma beats Innovate Biopharmaceuticals on 3 of the 5 factors compared between the two stocks. Get Innovate Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INNT vs. The Competition Export to ExcelMetricInnovate BiopharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8K$789.32M$5.51B$8.95BDividend YieldN/A4.84%5.25%4.04%P/E Ratio-1.791.3027.9920.16Price / SalesN/A227.08411.53174.36Price / CashN/A23.4437.0657.97Price / BookN/A6.138.145.62Net Income-$27.05M-$27.58M$3.16B$248.50M Innovate Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A$8KN/A-1.798SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00flatN/A-90.3%$13KN/A0.0090Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeCMRAComera Life SciencesN/A$0.00flatN/A-99.3%$6K$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5K$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020CLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560EFTReFFECTOR Therapeutics0.1686 of 5 stars$0.00flatN/A-99.6%$1K$3.55M0.0010Gap DownMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies SCPS Competitors VAXX Competitors EVLO Competitors CMRA Competitors ARDS Competitors STAB Competitors CLVR Competitors EFTR Competitors MTEM Competitors ONCSQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INNT) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
